5 hours Ago
Nektar Therapeutics ( NASDAQ: NKTR ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Brian Kotzin - Interim Chief Medical Officer Jonathan Zalevsky - Chief Research & Development Officer Sandra Gardiner - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Julian Harrison - BTIG Jay Olson - Oppenheimer Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Arthur He - H.C.
Wainwright Operator Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.
After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Vivian Wu.
Please go ahead. Vivian Wu Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today.
With us on the call are Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; Dr. Brian Kotzin, our Interim Chief Medical Officer; and Sandra Gardiner, our Chief Financial Officer.
On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the therapeutic potential of and future development plans for drug candidates and research programs, the timing of initiation of clinical studies and the availability of clinical data for drug candidates, the timing and plans for future clinical data presentations, the formation, future development plans or success of our collaboration agreements, financial guidance and certain other statements regarding the future of our business. Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult to predict, many of.
